Kodiak Sciences - מכפיל EV/Sales KOD

kodiak.com (KOD) - לוגו תאגידי

Kodiak Sciences Inc. (KOD) develops long-acting retinal treatments via the ABC platform. The EV/Sales ratio trajectory on the GURU.Markets chart indicates that the 0.00 mark serves as a key metric. The company plans to generate revenue from the commercialization of tarcocimab tedromer for macular degeneration. However, the absence of current sales and future price competition limit the company's pricing power.

KOD שווי חברה להכנסות Kodiak Corp (23.11.2025 - 20.11.2026)

Kodiak Corp - פילוחים אנליטיים ומדדי מפתח (KOD)

- מחיר שוק ויעדי מחיר של אנליסטים:
- מדדי מזומנים ותזרימי מזומנים:
הערכת שווי פונדמנטלית של החברה:KOD (Kodiak Sciences Inc.)
מוצר מקורי של Kodiak Pharma

Defensive asset screening requires an analysis of business value relative to revenue, excluding debt load. This metric compares market capitalization and net debt against annual turnover to determine the price per unit of sales. For Kodiak Sciences Inc. (KOD) during a period of risky clinical trials, this metric reflects a speculative valuation of future successes. The EV/Sales ratio here captures market optimism or skepticism regarding the commercialization of drugs.